Comments on: Pfizer’s pipeline http://www.kevinmd.com/blog/2007/10/pfizers-pipeline.html Tue, 14 Feb 2012 11:46:00 +0000 hourly 1 By: RJShttp://www.kevinmd.com/blog/2007/10/pfizers-pipeline.html#comment-81054 RJS Wed, 17 Oct 2007 04:03:00 +0000 http://clients.emmense.com/kevinmd/2007/10/pfizers-pipeline.html#comment-81054 Dr Schoor, they're already trying this crap with Caduet. Granted, Lipitor is still patent-protected, but it's clear they're thinking along the same lines. Torcetrapib was going to be their lifesaver. No more, I guess.<br/><br/>(Incidentally, Sanofi-Aventis has just done something similar with <a HREF="http://onthepharm.net/2007/10/levocetirizine-pointless-drug.html" REL="nofollow">Xyzal</a>.)<br/><br/>The very definition of "lame".<br/><br/>I would be crapping my pants if I were the CEO of a big drug company right now. They've spent so much time and effort evergreening existing products that they've forgotten that basic research is the best way to make serious money. And that doing it effectively requires lots of <i>time</i>. Even companies with <a HREF="http://onthepharm.net/2007/04/how-sepracor-could-make-a-buttload-of-money.html" REL="nofollow">a product that's actually better than the competition</a> are undercapitalizing on their opportunities. It's the height of folly.<br/><br/>I see a big crash in Big Pharma's collective stock prices in the near future. It's too late to effect a pipeline turnaround unless they buy a pre-existing company's IP portfolio. And there just aren't that many companies with much in the way of promising new drug therapies that can be bought out. Dr Schoor, they’re already trying this crap with Caduet. Granted, Lipitor is still patent-protected, but it’s clear they’re thinking along the same lines. Torcetrapib was going to be their lifesaver. No more, I guess.

(Incidentally, Sanofi-Aventis has just done something similar with Xyzal.)

The very definition of “lame”.

I would be crapping my pants if I were the CEO of a big drug company right now. They’ve spent so much time and effort evergreening existing products that they’ve forgotten that basic research is the best way to make serious money. And that doing it effectively requires lots of time. Even companies with a product that’s actually better than the competition are undercapitalizing on their opportunities. It’s the height of folly.

I see a big crash in Big Pharma’s collective stock prices in the near future. It’s too late to effect a pipeline turnaround unless they buy a pre-existing company’s IP portfolio. And there just aren’t that many companies with much in the way of promising new drug therapies that can be bought out.

]]> By: The Independent Urologisthttp://www.kevinmd.com/blog/2007/10/pfizers-pipeline.html#comment-81028 The Independent Urologist Tue, 16 Oct 2007 20:20:00 +0000 http://clients.emmense.com/kevinmd/2007/10/pfizers-pipeline.html#comment-81028 Here is the solution. Engineer an enantiomer of an existing drug like detrol LA, and re-patent it. Then market this "new" drug as a breakthough drug for over active bladder. Problem: solved. Alternatively they can combine 2 off-patent drugs, such as a detrol-hytrin combo drug, and sell this as a breakthrough agent. Perhaps they can call it Prostaspaz. With some marketing and FDA pay-outs, voila, a new blockbuster. Here is the solution. Engineer an enantiomer of an existing drug like detrol LA, and re-patent it. Then market this “new” drug as a breakthough drug for over active bladder. Problem: solved. Alternatively they can combine 2 off-patent drugs, such as a detrol-hytrin combo drug, and sell this as a breakthrough agent. Perhaps they can call it Prostaspaz. With some marketing and FDA pay-outs, voila, a new blockbuster.

]]> By: The Independent Urologisthttp://www.kevinmd.com/blog/2007/10/pfizers-pipeline.html#comment-81027 The Independent Urologist Tue, 16 Oct 2007 20:14:00 +0000 http://clients.emmense.com/kevinmd/2007/10/pfizers-pipeline.html#comment-81027 They can always make an enantiomer of, say, detrol, and re-market it as a breakthrough new drug for overactive bladder. Worked for Astra-Zeneca and Nexium. They can always make an enantiomer of, say, detrol, and re-market it as a breakthrough new drug for overactive bladder. Worked for Astra-Zeneca and Nexium.

]]>